U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937970) titled 'Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion' on April 14.
Brief Summary: This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Study Start Date: June 09, 2022
Study Type: INTERVENTIONAL
Condition:
Mesothelioma
Non Small Cell Lung Cancer
Malignant Peripheral Nerve Sheath Tumors
Solid Tumor
Pancreatic Adenocarcinoma
Advanced Solid Tumor
Intervention:
DRUG: MRTX1719
MRTX1719 is a potent PRMT5-MTA inhibitor
Specified dose on spe...